CPP21 – InsilicoPROTACs

CPP2021-08597

The InSilicoPROTACs project addresses one of today’s greatest medical challenges: breast cancer, a disease expected to affect more than 3.5 million people worldwide by 2050. Despite advances in chemotherapy and targeted therapies, resistance and side effects often limit their effectiveness, and for aggressive subtypes such as triple-negative or advanced HER2+ breast cancer, effective treatments are still lacking. To respond to this urgent need, InSilicoPROTACs combines artificial intelligence, in-silico molecular design, and nanomedicine to develop next-generation PROTACs and nanoPROTACs—innovative therapeutic agents designed to degrade key cancer-driving proteins with greater precision, safety, and efficacy. By joining the expertise of Cancerappy, a pioneering AI-driven biotech company, and the University of Castilla-La Mancha’s research group led by Dr. Carlos Alonso Moreno, this public–private partnership aims to create breakthrough personalised therapies that could transform the clinical management of breast cancer and position Europe at the forefront of oncology innovation

This project proposes the use of In-silico tools for the generation of more effective PROTACs for breast cancer treatment, as well as the formulation of PROTACs release systems through the use of nanotechnology in order to improves their pharmacology profile.

COMPUTATIONAL DESIGN OF NOVEL NANOPROTACS

The InSilicoPROTACs project aims to propose new alternatives of targeted therapies to improve the treatment of breast cancer based on the use of In-silico tools.  

  • In-silico identification of therapeutic targets
  • In-silico identification of membrane proteins.
  • Identification of a first lead (Lead identification).
  • Lead optimization (Optimization of leads).

 

EXPECTED OUTCOMES

  • Development of novel therapeutic agents for breast cancer using innovative In-silico design.
  • Novel drug delivery systems as personalized medicines for BC treatment.
  • Opportunity to develop innovative therapies for treating BC, based on new PROTACS and nanoPROTACs.
  • Opens a window for the treatment of other types of cancer.
  • Developed technology may path the way for new personalized medicines for several diseases
  • The discovery of novel therapeutic targets based on nanomedicine and its preclinical model’s validation.
  • The development of new PROTACS and nanoPROTACs molecules as treatment against breast cancer and potentially exploitable by Cancerappy
  • Better insights to guide the development of novel therapeutic agents to improve treatments in breast cancer.
insilicoPROTACs cancerappy
h

Publications and Scientific Papers

CPP21 – InsilicoPROTACs

Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total budget of €757,000 and a project duration of 3 years.